Isabel Hurtado1,2, Aníbal García-Sempere1,2, Salvador Peiró1,2, Gabriel Sanfélix-Gimeno1,2. 1. Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), València, Spain. 2. Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), València, Spain.
Abstract
Background: The opioid epidemic has been extensively documented in the United States and Canada, but fewer data are available for Europe. Aim: To describe the trends in opioid use-volume of prescriptions, dosage and number of patients treated-in a Spanish population with more than 4.2 million inhabitants aged 18 years and older. Patients and Methods: Population-based cross-sectional analysis of opioid prescription in adults (≥18 years) from January 1, 2010 to December 31, 2018 in the region of Valencia, Spain. Outcomes were estimated on an annual basis: number of prescriptions, prescription rate per 100 inhabitants, dosage per capita (morphine mg equivalents, MME/c) and volume of patients treated (overall and by drug). Results: Over the study period, 2,107,756 unique patients were prescribed more than 35 million total treatments. The yearly number of treatments doubled, and total MME/c showed almost a threefold increase. Fentanyl MME/c more than tripled, accounting for 34.4% of the total MME/c in 2018. Oxycodone MME/c showed a 10-fold increase, while tapentadol, launched in 2011, showed the highest growth rates. The annual number of patients receiving at least one opioid prescription more than doubled, from 335,379 in 2010 to 722,838 in 2018. Conclusions: Even if proportions still seem far from epidemic, urgent research is warranted on the observed patterns of use, their appropriateness and their association with health and safety outcomes, especially for high-use and high-strength drugs.
Background: The opioid epidemic has been extensively documented in the United States and Canada, but fewer data are available for Europe. Aim: To describe the trends in opioid use-volume of prescriptions, dosage and number of patients treated-in a Spanish population with more than 4.2 million inhabitants aged 18 years and older. Patients and Methods: Population-based cross-sectional analysis of opioid prescription in adults (≥18 years) from January 1, 2010 to December 31, 2018 in the region of Valencia, Spain. Outcomes were estimated on an annual basis: number of prescriptions, prescription rate per 100 inhabitants, dosage per capita (morphine mg equivalents, MME/c) and volume of patients treated (overall and by drug). Results: Over the study period, 2,107,756 unique patients were prescribed more than 35 million total treatments. The yearly number of treatments doubled, and total MME/c showed almost a threefold increase. FentanylMME/c more than tripled, accounting for 34.4% of the total MME/c in 2018. OxycodoneMME/c showed a 10-fold increase, while tapentadol, launched in 2011, showed the highest growth rates. The annual number of patients receiving at least one opioid prescription more than doubled, from 335,379 in 2010 to 722,838 in 2018. Conclusions: Even if proportions still seem far from epidemic, urgent research is warranted on the observed patterns of use, their appropriateness and their association with health and safety outcomes, especially for high-use and high-strength drugs.
Authors: J García del Pozo; A Carvajal; A M Rueda de Castro; M I Cano del Pozo; L H Martín Arias Journal: Eur J Clin Pharmacol Date: 1999-11 Impact factor: 2.953
Authors: Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander Journal: Annu Rev Public Health Date: 2015-01-12 Impact factor: 21.981
Authors: Benedikt Fischer; Thepikaa Varatharajan; Kevin Shield; Jürgen Rehm; Wayne Jones Journal: Drug Alcohol Depend Date: 2018-05-29 Impact factor: 4.492
Authors: Gerard Arnoldus Kalkman; Cornelis Kramers; Robert T van Dongen; Wim van den Brink; Arnt Schellekens Journal: Lancet Public Health Date: 2019-08-20
Authors: Brian J Piper; Dipam T Shah; Olapeju M Simoyan; Kenneth L McCall; Stephanie D Nichols Journal: Am J Prev Med Date: 2018-03-15 Impact factor: 5.043
Authors: Junqing Xie; Victoria Y Strauss; Daniel Martinez-Laguna; Cristina Carbonell-Abella; Adolfo Diez-Perez; Xavier Nogues; Gary S Collins; Sara Khalid; Antonella Delmestri; Aleksandra Turkiewicz; Martin Englund; Mina Tadrous; Carlen Reyes; Daniel Prieto-Alhambra Journal: JAMA Date: 2021-10-19 Impact factor: 56.272
Authors: Aníbal García-Sempere; Isabel Hurtado; Salvador Peiró; Francisco Sánchez-Sáez; Clara Liliana Rodríguez-Bernal; Magda Puig-Ferrer; Manuel Escolano; Gabriel Sanfélix-Gimeno Journal: Front Pharmacol Date: 2022-04-05 Impact factor: 5.988
Authors: Heather E Van Brug; Rob G H H Nelissen; Willem M Lijfering; Liza N Van Steenbergen; Frits R Rosendaal; Eveline L A Van Dorp; Marcel L Bouvy; Albert Dahan; Maaike G J Gademan Journal: Acta Orthop Date: 2022-07-15 Impact factor: 3.925
Authors: Junqing Xie; Victoria Y Strauss; Gary S Collins; Sara Khalid; Antonella Delmestri; Aleksandra Turkiewicz; Martin Englund; Mina Tadrous; Carlen Reyes; Daniel Prieto-Alhambra Journal: Front Pharmacol Date: 2022-06-08 Impact factor: 5.988
Authors: Jennifer Mirabella; Deepa Ravi; Angela L Chiew; Nicholas A Buckley; Betty S Chan Journal: Br J Clin Pharmacol Date: 2022-07-07 Impact factor: 3.716